Division of Internal Medicine, Department of Gastroenterology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
Department of Internal Medicine,İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
Turk J Gastroenterol. 2023 Apr;34(4):322-331. doi: 10.5152/tjg.2023.22003.
This study aimed to find the prevalence of gastrointestinal symptoms in hospitalized COVID-19 patients and to investigate the effects of gastrointestinal symptoms on the course of the disease during hospitalization.
Patients who were hospitalized due to COVID-19 were included in this retrospective study. The diagnostic method of COVID-19 was either a positive reverse transcription polymerase chain reaction test or a typical finding in chest computed tomography. This study was conducted by contacting patients by phone 1 month after they were discharged from hospital to investigate gastrointestinal symptoms. Patients' laboratory findings at the time of admission, medications they used, and clinical findings were obtained from hospital records retrospectively. Patients with gastrointestinal symptoms were divided into 2 groups according to the start of treatment: pre-treatment and post-treatment groups.
At least 1 gastrointestinal symptom (anorexia, weight loss, diarrhea, nausea, vomiting, and abdominal pain) was present in 67.5% of 435 patients (55.6% male, mean age 52.8). If anorexia and weight loss are excluded, the rate of the presence of at least 1 gastrointestinal symptom is 54%. Gastrointestinal symptoms were present in 48.9% before the initiation of COVID-19 treatment. The most prevalent 3 symptoms were anorexia, weight loss, and diarrhea (56%, 52%, and 35.6%, respectively). Presence of pre-treatment gastrointestinal symptoms was associated with elevated C-reactive protein levels. Pre-treatment gastrointestinal symptoms were more common in those who received oxygen supply and who were intubated. Resolution of gastrointestinal symptoms takes longer time in those who were admitted to intensive care unit. Weight loss and diarrhea were more common in COVID-19 patients with gastrointestinal symptoms who were intubated than who were not intubated. Abdominal pain was not found to be a significant predictor of disease severity.
The prevalence of at least 1 gastrointestinal symptom in hospitalized COVID-19 patients was 67%. The most prevalent symptoms were anorexia, weight loss, and diarrhea. Presence of pre-treatment gastrointestinal symptoms was associated with elevated C-reactive protein levels, use of oxygen supply, and intubation. Gastrointestinal symptoms persist longer in those admitted to intensive care unit.
本研究旨在调查住院 COVID-19 患者胃肠道症状的发生率，并探讨胃肠道症状对住院期间疾病进程的影响。
本回顾性研究纳入了因 COVID-19 住院的患者。COVID-19 的诊断方法为阳性逆转录聚合酶链反应检测或胸部计算机断层扫描的典型表现。本研究通过电话联系患者，在出院后 1 个月时调查胃肠道症状。通过回顾性获取病历，获得患者入院时的实验室检查结果、使用的药物和临床发现。根据治疗开始时间将有胃肠道症状的患者分为 2 组：治疗前组和治疗后组。
435 例患者中至少存在 1 种胃肠道症状（食欲不振、体重减轻、腹泻、恶心、呕吐和腹痛）的患者占 67.5%（55.6%为男性，平均年龄为 52.8 岁）。如果排除食欲不振和体重减轻，则至少存在 1 种胃肠道症状的发生率为 54%。在开始 COVID-19 治疗前，胃肠道症状的发生率为 48.9%。最常见的 3 种症状为食欲不振、体重减轻和腹泻（分别为 56%、52%和 35.6%）。治疗前存在胃肠道症状与 C 反应蛋白水平升高有关。接受氧气供应和插管的患者胃肠道症状更为常见。在重症监护病房住院的患者胃肠道症状缓解时间更长。有胃肠道症状且插管的 COVID-19 患者比未插管的患者更常出现体重减轻和腹泻。腹痛并非疾病严重程度的显著预测指标。
住院 COVID-19 患者至少存在 1 种胃肠道症状的发生率为 67%。最常见的症状为食欲不振、体重减轻和腹泻。治疗前存在胃肠道症状与 C 反应蛋白水平升高、接受氧气供应和插管有关。在重症监护病房住院的患者胃肠道症状持续时间更长。
